63 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 hinder the 4-5x investment needed, while ESG compliance still lags behind Western peers. In a step toward advancing India’s CRDMO sector, eleven of the country’s leading CRDMO companies have come together to launch a dedicated industry body called IPSO, bringing together diverse expertise in discovery, development, biomanufacturing, and other specialized areas. This collective initiative aims to advance India’s CRDMO sector and is dedicated to fostering pharmaceutical and healthcare innovation in India, that supports research, policy advocacy and industry collaboration to drive the next wave of biotech and pharma growth. Peter Bains, CEO Designate, Syngene International Ltd., emphasized the importance of such collaborations among all stakeholders to realize growth. “The Indian CRDMO sector is positioned for major transformation, with the potential to become a leader in serving the global biopharma and wider life sciences outsourcing market models. Realizing this opportunity will require change and collaboration among all stakeholders in the Indian CRDMO ecosystem. As leading industry players, we must express vision, ambition and intent to move beyond our recognized strengths in small molecules development and manufacturing and into new technologies and modalities, in order to realize the inherent potential. We will also need to work with and collaborate with the Government to foster a more competitive regulatory and financial ecosystem in India to compete with other geographies. We will need to work with India’s academic ecosystem to ensure a strong flow of highly talented scientists, engineers and technology leaders to ensure we are capability competitive. Only by working together, can we unlock new opportunities in drug discovery, process innovation, and advanced manufacturing, that can strengthen India’s position in the global pharmaceutical value chain. This is where IPSO serves as a catalyst, bringing together leading CRDMOs to drive advocacy, build an ecosystem of innovation, and address critical challenges such as supply chain resilience and regulatory efficiencies. But no single organization can do this alone—it is the collective effort of the entire ecosystem that will enable India to move beyond being a cost-efficient outsourcing hub to a strategic global partner for cutting-edge R&D and biopharmaceutical manufacturing.” Manni Kantipudi, CEO and Whole time Director, Aragen Life Sciences Ltd., adds, “India’s CRDMO sector has all the right ingredients to scale from its current $3-3.5 billion market to $22-25 billion by 2035. The shift in global pharma outsourcing, the rapid rise of biologics, and India’s expertise in chemistry and process innovation create a once-in-a-generation opportunity. However, to compete at a global level, Indian CRDMOs must not only scale capabilities in new modalities like ADCs, cell & gene therapies, and RNA therapeutics but also work together to build a resilient supply chain and streamline regulatory pathways. IPSO is committed to driving this change by working closely with stakeholders to improve access to capital, accelerate talent development, and champion BCG-IPSO REPORT
RkJQdWJsaXNoZXIy MjY2OTA4MA==